ID   HROG02
AC   CVCL_4U38
DR   cancercelllines; CVCL_4U38
DR   CLS; 300931
DR   PRIDE; PXD020079
DR   Wikidata; Q54895307
RX   PubMed=23951083;
RX   PubMed=33592498;
CC   From: Linnebacher, Michael; University of Rostock; Rostock; Germany.
CC   Population: Caucasian.
CC   Doubling time: 36-54 hours (CLS=300931).
CC   HLA typing: A*01:01,02:01; B*08:01,13:02; C*06:02,07:01; DPA1*01:03; DPB1*04:01; DQA1*02:01,05:01; DQB1*02:01,02:02; DRB1*03:01,07:01; DRB3*01:01; DRB4*01:03 (PubMed=33592498).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=23951083).
CC   Omics: Deep exome analysis.
CC   Omics: HLA class I peptidome analysis by proteomics.
CC   Omics: HLA class II peptidome analysis by proteomics.
CC   Derived from site: In situ; Brain, right parieto-occipital lobe.
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   68Y
CA   Cancer cell line
DT   Created: 22-09-15; Last updated: 19-12-24; Version: 17
//
RX   PubMed=23951083; DOI=10.1371/journal.pone.0071070; PMCID=PMC3737284;
RA   Mullins C.S., Schneider B., Stockhammer F., Krohn M., Classen C.F.,
RA   Linnebacher M.;
RT   "Establishment and characterization of primary glioblastoma cell lines
RT   from fresh and frozen material: a detailed comparison.";
RL   PLoS ONE 8:E71070-E71070(2013).
//
RX   PubMed=33592498; DOI=10.1074/mcp.RA120.002201; PMCID=PMC8724627;
RA   Forlani G., Michaux J., Pak H., Huber F., Lauret Marie-Joseph E.,
RA   Ramia E., Stevenson B.J., Linnebacher M., Accolla R.S.,
RA   Bassani-Sternberg M.;
RT   "CIITA-transduced glioblastoma cells uncover a rich repertoire of
RT   clinically relevant tumor-associated HLA-II antigens.";
RL   Mol. Cell. Proteomics 20:100032.1-100032.21(2021).
//